MSLENasdaqPharmaceutical PreparationsFiscal year ends December 31

Satellos Bioscience Inc.

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 40-F on Mar 27, 2026

$6.44−0.02 (-0.31%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): –
Dividend yield: –

Satellos Bioscience Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31
Cash & Equivalents	9.80	40	17
Cash & Short-Term Investments	9.80	40	17
Total Current Assets	32	51	30
Property, Plant & Equipment	0.01	0.00	0.02
Total Assets	32	51	33
Accounts Payable	4.11	3.58	2.73
Total Current Liabilities	4.11	3.58	2.73
Total Liabilities	4.11	3.58	2.73
Common Stock	86	78	47
Retained Earnings	-82	-57	-36
Total Equity	28	47	31
Total Liabilities & Equity	32	51	33

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Dec 31, 2025

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: –

Financial strength

Current ratio: 7.77
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 238.8%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –